Core Insights - Chutian Technology is transforming from manufacturing to intelligent manufacturing in the pharmaceutical equipment sector, showcasing its capabilities at the 2025 headquarters factory open day event attended by over 130 pharmaceutical leaders from nearly 30 countries [1] Group 1: Company Overview - Chutian Technology focuses on pharmaceutical equipment and has over ten subsidiaries, including Romaco Holding GmbH and Chutian Microsphere Biotechnology, enabling it to provide comprehensive solutions from laboratory research to commercial production [2] - The company has developed a "smart pharmaceutical factory" ecosystem, emphasizing the importance of key consumables in the innovative drug development process [2][3] Group 2: Product and Technology - Chutian Technology's products include high-tech disposable bioreactor bags for cell culture, which utilize a proprietary 11-layer biocomposite membrane, offering superior physical properties compared to imported alternatives [2] - The company specializes in chromatography media technology, with products certified by the US FDA, supporting the purification of biopharmaceuticals [3] Group 3: Industry Trends - The Chinese regulatory environment is evolving, with new guidelines promoting high-quality development in sterile drug production, driving demand for modular and flexible pharmaceutical equipment [3] - The trend towards small-batch production of diverse drugs is pushing the industry towards more intelligent and higher-specification equipment [3] Group 4: Global Strategy - Chutian Technology aims to become a global leader in pharmaceutical equipment by leveraging its acquisition of Romaco to enhance its international presence [6] - The company has exported products to over 40 countries and regions, with new domestic export orders exceeding 1.2 billion yuan in 2024, marking a significant entry into high-end markets [6] Group 5: Operational Excellence - The company employs digital technologies such as SCADA, MES, and digital twin technology to enhance product traceability and real-time monitoring throughout the production process [4] - Chutian Technology has established a dual-headquarters model, with its headquarters in Changsha focusing on basic research and Romaco in Germany serving the European and American markets, creating a synergistic operational framework [7] Group 6: Future Goals - The company aims to become a leading global pharmaceutical equipment group by 2030, enhancing its international competitiveness and brand influence in the pharmaceutical sector [7]

Core Viewpoint - The article highlights the dedication and innovation of young workers in precision machining, exemplified by Huang Zhongqin, who has become a key technical talent at Chutian Technology through hard work and creativity [1][4]. Group 1: Individual Achievement - Huang Zhongqin, a young craftsman from Huaihua, has excelled in the precision machining field, overcoming challenges and achieving a high technical level in just four years, which typically takes ten years [4][7]. - He won a provincial second prize in a skills competition while studying at Zhangjiajie Aviation Vocational Technical College, which led to his recruitment by Chutian Technology [4]. Group 2: Innovation and Collaboration - Huang faced difficulties with a special connecting rod that repeatedly failed due to stress deformation, prompting him to innovate by creating a new bonding method and refining the process [4][6]. - He promotes a culture of knowledge sharing in the workplace, combining technical skills learned in school with practical experience from senior workers, fostering a collaborative environment [4][6]. Group 3: Industry Environment - The article emphasizes the supportive industrial ecosystem in Changsha, which nurtures talent and innovation in smart manufacturing, attracting young professionals like Huang [7]. - Huang expresses a strong commitment to contributing to the future of the industry and embodies the spirit of craftsmanship, which is crucial for the development of precision manufacturing [7].

| 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-044 | 号 | | --- | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | | 楚天科技股份有限公司 关于 2025 年第二季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、楚天转债（债券代码：123240）转股期限为 2024 年 8 月 6 日至 2030 年 1 月 30 日，最新有效的转股价格为人民币 8.00 元/股。 2、2025 年第二季度，共有 0 张"楚天转债"完成转股（票面金额 0 元人民 币），转换成"楚天科技"股票 0 股。 3、截至 2025 年第二季度末，楚天科技股份有限公司（以下简称"公司"） 剩余可转换公司债券（以下简称"可转债"）为 9,999,810 张，剩余票面总金额 为 99,998.10 万元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，公司现将 2025 ...

| 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-043 | 号 | | --- | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | | 楚天科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 目前，公司已完成相关工商变更登记、章程备案等手续，并取得了长沙市市场 监督管理局换发的《营业执照》，变更登记后的公司基本情况如下： 一、基本登记信息 1、统一社会信用代码：91430100743176293C 5、法定代表人：唐岳 许可项目：电气安装服务；特种设备安装改造修理；特种设备设计；建设工程 施工；第二类医疗器械生产；消毒器械生产；消毒器械销售；特种设备制造。(依 2、名称：楚天科技股份有限公司 3、类型：股份有限公司（上市、自然人投资或控股） 4、住所：宁乡市玉潭镇新康路 1 号 楚天科技股份有限公司（以下简称"公司"）于 2025 年 4 月 26 日召开第五届 董事会第三十四次会议，审议通过了《关于变更注册资本暨修订<公司章程> ...

债券简称：楚天转债 债券代码：123240.SZ 国金证券股份有限公司 关于楚天科技股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024 年度） 发行人 楚天科技股份有限公司 （湖南省长沙市宁乡市玉潭镇新康路 1 号） 债券受托管理人 （住所：成都市青羊区东城根上街 95 号） 声明 根据《可转换公司债券管理办法》、 《公司债券受托管理人执业行为准则（2023 年修订） 》、交易所关于定期受托管理事务报告的规定要求，以及相关债券受托管 理协议、募集说明书等相关约定，国金证券股份有限公司（以下简称"国金证券"） 作为受托管理人，以公开信息披露文件、发行人出具的相关说明文件以及第三方 中介机构出具的专业意见等为信息来源编制本定期受托管理事务报告。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为国金证券所作的承诺 或声明。未经国金证券书面许可，不得将本报告用作其他任何用途。 二、募集资金专项账户运作情况与核查情况 第一章 本次可转债基本情况 一、核准文件及核准规模 本次发行已经楚天科技股份有限公司（以下简称"楚天科技"、 ...

1 联合〔2025〕5123 号 联合资信评估股份有限公司通过对楚天科技股份有限公司主体 及其相关债券的信用状况进行跟踪分析和评估，确定维持楚天科技 股份有限公司主体长期信用等级为 AA，维持"楚天转债"信用等级 为 AA，评级展望为稳定。 特此公告 楚天科技股份有限公司 向不特定对象发行可转换公司债券 2025 年跟踪评级报告 www.lhratings.com 联合资信评估股份有限公司 评级总监： 二〇二五年六月二十四日 跟踪评级报告 | 2 声 明 一、本报告是联合资信基于评级方法和评级程序得出的截至发表之日的 独立意见陈述，未受任何机构或个人影响。评级结论及相关分析为联合资信基 于相关信息和资料对评级对象所发表的前瞻性观点，而非对评级对象的事实 陈述或鉴证意见。联合资信有充分理由保证所出具的评级报告遵循了真实、客 观、公正的原则。鉴于信用评级工作特性及受客观条件影响，本报告在资料信 息获取、评级方法与模型、未来事项预测评估等方面存在局限性。 二、本报告系联合资信接受楚天科技股份有限公司（以下简称"该公 司"）委托所出具，除因本次评级事项联合资信与该公司构成评级委托关系 外，联合资信、评级人员与该公司不 ...

债券简称：楚天转债 债券代码：123240.SZ 楚天科技股份有限公司 （湖南省长沙市宁乡市玉潭镇新康路 1 号） 债券受托管理人 国金证券股份有限公司 关于楚天科技股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024 年度） 发行人 （住所：成都市青羊区东城根上街 95 号） 2025 年 6 月 1 声明 根据《可转换公司债券管理办法》、《公司债券受托管理人执业行为准则（2023 年修订）》、交易所关于定期受托管理事务报告的规定要求，以及相关债券受托管 理协议、募集说明书等相关约定，国金证券股份有限公司（以下简称"国金证券"） 作为受托管理人，以公开信息披露文件、发行人出具的相关说明文件以及第三方 中介机构出具的专业意见等为信息来源编制本定期受托管理事务报告。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为国金证券所作的承诺 或声明。未经国金证券书面许可，不得将本报告用作其他任何用途。 2 | 声明 2 | | | --- | --- | | 目录 3 | | | 第一章 | 本次可转债基本情况 4 | | 一 ...

Summary of Key Points Core Viewpoint - Chutian Technology Co., Ltd. has successfully completed its obligation to repurchase equity from the National Development Fund for its subsidiary, Chutian Intelligent Robot (Changsha) Co., Ltd., and has fully released its guarantee obligations to Ningxiang Economic Development Group [1][4]. Group 1: Guarantee Overview - Chutian Technology provided a counter-guarantee for Ningxiang Economic Development Group, which was a third-party guarantee for a 60 million yuan investment from the National Development Fund to Chutian Intelligent Robot [1]. - The guarantee was secured by the company's own land and properties located in Changsha, with a total guarantee amount of 60 million yuan and a term of 15 years [1]. Group 2: Guarantee Progress - As of the announcement date, the company has completed the repurchase of all equity from the National Development Fund, making Chutian Robot a wholly-owned subsidiary [4]. - The company has fully released its counter-guarantee responsibilities to Ningxiang Economic Development Group, and there are no remaining guarantee obligations [4]. Group 3: Other Information - The actual guarantee balance of the company is 927.74 million yuan, which accounts for 6.97% of the company's audited total assets and net assets for the year 2024 [4].

| 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-042 | 号 | | --- | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | | 楚天科技股份有限公司 关于公司对外担保进展暨解除对外担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、对外担保情况概述 楚天科技股份有限公司（以下简称"楚天科技""公司"）于 2016 年 3 月 3 日召开第二届董事会第二十三次会议，审议通过了《关于公司为长沙蓝月谷实业 集团有限公司提供反担保的议案》。国开发展基金有限公司（以下简称"国开发 展基金"）为楚天科技子公司楚天智能机器人（长沙）有限公司（以下简称"楚 天机器人"）以增资方式提供 6000 万元资金支持，期限 15 年。楚天科技对该笔 增资形式的股权提供回购承诺，并委托长沙蓝月谷实业集团有限公司（现更名为： 宁乡经开区实业集团有限公司，以下简称"宁乡经开实业集团"）为上述回购 及国开发展基金每年的投资收益提供第三方连带责任保证担保。公司以位于长沙 市宁乡县楚天科技工业园内的自有 ...

Core Viewpoint - The company is actively expanding its international market presence and has established localized sales and service networks in over ten key countries and regions, aiming to enhance its global competitiveness and brand influence in the pharmaceutical equipment sector [1][4]. Group 1: International Market Expansion - The company has strategically divided its global operations into five regional departments to strengthen its international sales and service capabilities [1]. - In 2024, the company expects to achieve over 1.2 billion in new export orders, with products entering high-end markets such as Europe [1][4]. - Major international pharmaceutical companies have initiated supplier audits for the company, indicating potential future collaborations [1]. Group 2: Order Delivery and Revenue Recognition - The manufacturing cycle for main products typically ranges from 3 to 9 months, with revenue recognition based on specific criteria for domestic and international orders [2]. - The impact of U.S. tariffs on the company's sales and supply chain is minimal, as exports to the U.S. constitute a small portion of overall revenue [2]. Group 3: Development in Specific Fields - The company has established a joint venture in the peptide synthesis equipment sector, with the subsidiary achieving sales and reporting total assets of approximately 15.61 million and a net loss of about 2.22 million for 2024 [3]. - The company is pioneering the development of smart pharmaceutical factories, focusing on integrating artificial intelligence into its production processes to enhance efficiency and user value [3].